TUEBINGEN, Germany, March 14, 2007--With the consent of the EU Commission, Tuebingen-based biotech company immatics has been granted orphan drug status from the European Medicines Agency (EMEA) for its product candidate IMA901 for the treatment of renal cell cancer. This gives immatics the exclusive rights to market and sell IMA901 in Europe for ten years following its market approval. 5 In addition, classification as an orphan drug also makes it eligible for a centralized approval procedure, thus affording faster approvals in all EU member countries.
